•
TA
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
3.02B
Volume
518.39K
52W High
$85.25
52W Low
$38.51
Open
$0.00
Prev Close
$70.93
Day Range
0.00 - 0.00
About Tarsus Pharmaceuticals, Inc. Common Stock
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Latest News
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
GlobeNewswire Inc.•Oct 28
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase
The Motley Fool•Oct 27
Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight
GlobeNewswire Inc.•Oct 1
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Aug 27
3 Biotech Catalysts Present Major Opportunity
Investing.com•Aug 27
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
GlobeNewswire Inc.•Jul 30
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•May 29
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Benzinga•May 5